


STRUCTURAL BIOLOGY

IMMUNOGLOBULINS

Júlia Brunet, Marta Nieto i Aina Pocerull

INTRODUCTION & CONCEPTS


ISOTYPES



STRUCTURE

LIGHT CHAIN

- Kappa
- Lambda



HEAVY CHAIN

1IGY

Mus musculus

3,2 Å


Fab

Antigen Binding


immunoglobulin superfamily (IgSF)

Fc


Crystallizable Region



STRUCTURE




1IGY
Mus musculus
3,2 Å




GERMLINE CONFIGURATION OF IMMUNOGLOBULIN GENES

Chromosome 2 - κ light chain locus



Chromosome 22 - λ light chain locus




Chromosome 14 - heavy chain locus




REARRANGEMENT

Chromosome 14 - heavy chain locus





REARRANGEMENT


Chromosome 2 - κ light chain locus



Chromosome 22 - λ light chain locus




IMMUNOGLOBULIN LIKE-FOLD




GREEK-KEY FOLD




IMMUNOGLOBULIN G




IgG1



IgG2



IgG3




IgG4

SCOP CLASSIFICATION



CLASS	All beta proteins
FOLD	Immunoglobuline - like β - sandwich
SUPERFAMILY	Immunoglobulin
FAMILY	V set domains C1 set domains C2 set domains


SECONDARY STRUCTURE




- beta-sheet
- alpha-helix
- helix
- turn
- coil

1IGY
Mus musculus
3,2 Å


TOPOLOGY




V Region




C Region




HYDROGEN BONDS



GLYCINE AND PROLINE



HYDROPHOBIC AND HYDROPHILIC RESIDUES






1IGY
Mus musculus
3,2 Å

HYDROPHILIC
energetically
advantageous




HYDROPHOBIC
repel water


DISULPHIDE BRIDGES



DISULPHIDE BRIDGES → INTRA-CHAIN




DISULPHIDE BRIDGES → HEAVY AND LIGHT CHAIN





DISULPHIDE BRIDGES → HINGE

Links CH1 and CH2 by S-S bonds




DISULPHIDE BRIDGES → HINGE



CONSTANT REGION

GLYCOSYLATION

● Glycosilations



Chain B




Chain A

GLYCOSYLATION FUNCTIONS


- FcγR recognition
- Antibody dependent cellular cytotoxicity (ADCC)
- Complement dependent cytotoxicity

3AVE
Homo sapiens
2,00 Å


GLYCOSYLATION





GLYCOSYLATION



IgG RECEPTORS



FcγR I





Chain B


Chain A

4X4M
Homo sapiens
3,48 Å


- Fc chain A - FcγRI





● Fc chain B - FcγRI



- Fc - FcγRI FC loop



IgG SUBTYPES



3AVE - IgG1 2Å
4HAF - IgG2 2,04Å
6D58 - IgG3 2,39Å
4C55 - IgG4 2,35Å

IgG SUBTYPES

0,86 { 0,78 { 0,57 {
 IgG4
 IgG2
 IgG1
 IgG3
 RMSD

Aspartate - 265
 Glutamate - 269 and 294

```


4c55  ---GPSVFLFPPKPKDTMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE 47
4haf  --AGPSVFLFPPKPKDTMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVE 48
3ave  LLGGPSVFLFPPKPKDTMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 50
6d58  ---GPSVFLFPPKPKDTMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVE 47
*****:*****:*****:*****

4c55  VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP-SSI 96
4haf  VHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSN-KGLPAPI 97
3ave  VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN-KALPAPI 99
6d58  VHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSN-KALPAPI 96
*****:*****:*****:*****+::*


4c55  EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE 146
4haf  EKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE 147
3ave  EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE 149
6d58  EKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE 146
*****:*****:*****:*****

4c55  SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 196
4haf  SNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL 197
3ave  SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL 199
6d58  SSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL 196
*.:*****:*****:*****:*****:*****

4c55  HNHYTQKSLSLSL 208
4haf  HNHYTQKSLSLSL 209
3ave  HNHYTQKSLSLSL 211
6d58  HNHFTQKSLSL- 207
*****:*****
    
```




IgG SUBTYPES




RMSD


4c55	---	G	P	S	V	F	L	F	P	P	K	P	K	D	T	L	M	I	S	R	T	P	E	V	T	C	V	V	D	V	S	Q	E	D	P	E	V	Q	F	N	W	Y	V	D	G	V	E	47								
4haf	--	A	G	P	S	V	F	L	F	P	P	K	P	K	D	T	L	M	I	S	R	T	P	E	V	T	C	V	V	D	V	S	H	E	D	P	E	V	Q	F	N	W	Y	V	D	G	V	E	48							
3ave	LL	G	G	P	S	V	F	L	F	P	P	K	P	K	D	T	L	M	I	S	R	T	P	E	V	T	C	V	V	D	V	S	H	E	D	P	E	V	K	F	N	W	Y	V	D	G	V	E	50							
6d58	---	G	P	S	V	F	L	F	P	P	K	P	K	D	T	L	M	I	S	R	T	P	E	V	T	C	V	V	D	V	S	H	E	D	P	E	V	Q	F	K	W	Y	V	D	G	V	E	47								
		*****:*****:*****																																																						
4c55	V	H	N	A	K	T	K	P	R	E	E	Q	F	N	S	T	Y	R	V	V	S	V	L	T	V	L	H	Q	D	W	L	N	G	K	E	Y	K	C	K	V	S	N	K	G	L	P	-	S	S	I	96					
4haf	V	H	N	A	K	T	K	P	R	E	E	Q	F	N	S	T	Y	R	V	V	S	V	L	T	V	V	H	Q	D	W	L	N	G	K	E	Y	K	C	K	V	S	N	-	K	G	L	P	A	P	I	97					
3ave	V	H	N	A	K	T	K	P	R	E	E	Q	Y	N	S	T	Y	R	V	V	S	V	L	T	V	L	H	Q	D	W	L	N	G	K	E	Y	K	C	K	V	S	N	-	K	A	L	P	A	P	I	99					
6d58	V	H	N	A	K	T	K	P	R	E	E	Q	Y	N	S	T	Y	R	V	V	S	V	L	T	V	L	H	Q	D	W	L	N	G	K	E	Y	K	C	K	V	S	N	-	K	A	L	P	A	P	I	96					
		*****:*****:*****+::*																																																						
4c55	E	K	T	I	S	K	A	K	G	Q	P	R	E	P	Q	V	Y	T	L	P	P	S	Q	E	E	M	T	K	N	Q	V	S	L	T	C	L	V	K	G	F	Y	P	S	D	I	A	V	E	W	E	146					
4haf	E	K	T	I	S	K	T	K	G	Q	P	R	E	P	Q	V	Y	T	L	P	P	S	R	E	E	M	T	K	N	Q	V	S	L	T	C	L	V	K	G	F	Y	P	S	D	I	A	V	E	W	E	147					
3ave	E	K	T	I	S	K	A	K	G	Q	P	R	E	P	Q	V	Y	T	L	P	P	S	R	D	E	L	T	K	N	Q	V	S	L	T	C	L	V	K	G	F	Y	P	S	D	I	A	V	E	W	E	149					
6d58	E	K	T	I	S	K	T	K	G	Q	P	R	E	P	Q	V	Y	T	L	P	P	S	R	E	E	M	T	K	N	Q	V	S	L	T	C	L	V	K	G	F	Y	P	S	D	I	A	V	E	W	E	146					
		*****:*****:*****																																																						
4c55	S	N	G	Q	P	E	N	N	Y	K	T	T	P	P	V	L	D	S	D	G	S	F	F	L	Y	S	R	L	T	V	D	K	S	R	W	Q	E	G	N	V	F	S	C	S	V	M	H	E	A	L	196					
4haf	S	N	G	Q	P	E	N	N	Y	K	T	T	P	P	M	L	D	S	D	G	S	F	F	L	Y	S	K	L	T	V	D	K	S	R	W	Q	Q	G	N	V	F	S	C	S	V	M	H	E	A	L	197					
3ave	S	N	G	Q	P	E	N	N	Y	K	T	T	P	P	V	L	D	S	D	G	S	F	F	L	Y	S	K	L	T	V	D	K	S	R	W	Q	Q	G	N	V	F	S	C	S	V	M	H	E	A	L	199					
6d58	S	S	G	Q	P	E	N	N	Y	T	T	P	P	M	L	D	S	D	G	S	F	F	L	Y	S	K	L	T	V	D	K	S	R	W	Q	Q	G	N	I	F	S	C	S	V	M	H	E	A	L	196						
		*.:*****:*****:*****:*****:*****																																																						
4c55	H	N	H	Y	T	Q	K	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	208				
4haf	H	N	H	Y	T	Q	K	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	209		
3ave	H	N	H	Y	T	Q	K	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	211
6d58	H	N	H	F	T	Q	K	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	S	L	207
		:**																																																						



LALA MUTANTS



IgG1 AMONG SPECIES



CH2



CH3

3HKF (*Mus musculus*) 2.50 Å
3AVE (*Homo sapiens*) 2.00 Å
6D4E (*Macaca mulatta*) 2.80 Å

IgG1 AMONG SPECIES

2,23

{ 0,99 }

Mus musculus
Homo sapiens
Macaca mulatta

RMSD

CLUSTAL W(1.60) multiple sequence alignment

```
3hkf  ----SSVFIFPPKPKDVLITITLTPKVTCVVVVDISKDD--PE-VQFSWFVDDVEVHTAQTQ
3ave  LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVVDV---SHEDPEVKFNWYVDGVEVHNAKTK
6d4e  ---GPSVFLFPPKPKDTLMISRTPEVTCVVVVDV---SQEDPDVKFNWYVNGAEVHHAQTK

3hkf  PRE-EQFNST--FRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQ
3ave  PREEQ---YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
6d4e  PRETQ---YNSTYRVVSVLTVTHQDWLNGKEYTCKVSNKALPAPIQKTISKDKGQPREPQ



3hkf  VYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVY
3ave  VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLY
6d4e  VYTLPPSREELTKNQVSLTCLVKGFYPSDIVVEWESSGQPENTYKTTTPVLDSGDSYFLY

3hkf  SKLNVQKSNWEAGNTFTCSVLHEGLHNHHTKSLS--
3ave  SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
6d4e  SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSVS
```

- DISULPHIDE BRIDGES




- ASPARAGINE




VARIABLE REGION

COMPLEMENTARITY-DETERMINING REGIONS (CDR)



CANONICAL STRUCTURES





Chothia classification

HEAVY CHAIN		canonical structure
H1		1, 2, 3
H2		1, 2a, 2b, 2c, 3a, 3b, 3c, 4
H3		-
LIGHT CHAIN		canonical structure
L1	LAMBDA (λ)	1 λ , 2 λ , 3a λ , 3b λ , 4 λ
	KAPPA (κ)	1k, 2k, 3ak, 3bk, 4k
L2		1
L3	LAMBDA (λ)	1a λ , 1b λ , 1c λ , 2 λ
	KAPPA (κ)	1k, 2k, 3k, 4k, 5k

LIGHT CHAIN (LAMBDA)

LIGHT CHAIN		canonical structure
L1	LAMBDA (λ)	1 λ , 2 λ , 3a λ , 3b λ , 4 λ
	KAPPA (κ)	1 κ , 2 κ , 3a κ , 3b κ , 4 κ
L2		I
L3	LAMBDA (λ)	1a λ , 1b λ , 1 λ c, 2 λ
	KAPPA (κ)	1 κ , 2 κ , 3 κ , 4 κ , 5 κ



CLUSTAL W(1.60) multiple sequence alignment

```


8fab      E--LTQPPSVSVSPGQTARITCSA-N-A--LP--NQYAYWYQQKPGRA-PVMVIYKDTQR
2rhe      ---LTQPPSASGTPGQRVTISCTG-S-ATDIG--SNSVIWYQQVP-GKAPKLLIYYNDLL
1mfa      I-VVTQESALTTSPGETVTLTCRSSTGT--VT-SGNHANWVQEKPDHL-FTGLIGDTNNR
7fab      ---LTQPPSVSGAPGQRVTISCTG-S-SSNIGAGH-NVKWYQQLPGTA-PKLL-----I
1gig      A-VVTQESALTTSPGETVTLTCRSSTGA--VT-TSNYANWVQEKPDHL-FTGLIGGTNNR
2fb4      QSVLTQPPSASGTPGQRVTISCSG-T-SSNIG--SSTVNWYQQLP-GMAPKLLIYRDAMR
1ind      A-VVTQESALTTSPGETVTLTCRSSTGA--VT-TSNYANWVQEKPDHL-FTGLIGGTNNR
    
```

```


8fab      PSGIPQRFSSSTSGTTVTLTISGVQAEDEADYYCQAWDN--SASIFGGGKTLTVLG---Q
2rhe      PSGVSDRFSASKSGTSASLAISGLESEDEADYYCAAWNDSLDEPGFGGGKTLTVLG---Q
1mfa      APGVPARFSGSLIGDKAALTITGAQPEDEAIYFCALWSN--NHWIFGGGKTLTVLGQGE-
7fab      FHN-NARFSVSKSGTSATLAITGLQAEDEADYYCQSYDR--SLRVFGGGKTLTVLR---Q
1gig      APGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYS--NHWVFGGGKTLTVLG---Q
2fb4      PSGVPDRFSGSKSGASASLAIGGLQSEDETDDYYCAAWDVSLNAYVFGTGTKVTVLG---Q
1ind      APGVPARFSGSLIGDKAALTITGAQTEDEARYFCALWYS--NLWVFGGGKTLTVLG---Q
    
```

L1 - λ3


1ind	TCRSSTGAVTTSNYAN
1mfa	TCRSSTGTVTSGNHAN
1gig	TCRSSTGAVTTSNYAN




1ind




1mfa




1gig



L2



1hil
kappa



2fb4
lambda



L3 - λ2

2fb4


2rhe

AAWDVSLNAYVF

AAWNDSLDEPGF





2rhe



7fab

LIGHT CHAIN (KAPPA)

LIGHT CHAIN		canonical structure
L1	LAMBDA (λ)	1 λ , 2 λ , 3a λ , 3b λ , 4 λ
	KAPPA (κ)	1 κ , 2 κ , 3a κ , 3b κ , 4 κ
L2		I
L3	LAMBDA (λ)	1a λ , 1b λ , 1 λ c, 2 λ
	KAPPA (κ)	1 κ , 2 κ , 3 κ , 4 κ , 5 κ



CLUSTAL W(1.60) multiple sequence alignment

```

1hil  STKVDKKIEPRDIVMTQSPSSLTVTAGEKVTMSCTSSQSLFNSGKQKNYLTWYQQKPGQP
2imm  -----DIVMTQSPSSLSVSAGERVTMSCKSSQSLLNNSGNQKNFLAWYQQKPGQP
1flr  -----DVVMTQTPLSLPLVSLGDDQASISCRSSQSLVH-SNGNTYLRWYLQKPGQS
1fvc  WGQGTLVTVSSDIQMTQSPSSLSASVGDRTVITCRASQDVN-----TAWAWYQQKPGKA
1igm  -----DIQMTQSPSSLSASVGDRTVITCQASQDIS-----NYLAWYQQKPGKA
1fgv  -----DIQMTQSPSSLSASVGDRTVITCRASQDIN-----NYLNWYQQKPGKA
1vfa  -----DIVLTQSPASLSASVGETVTITCRASGNIH-----NYLAWYQQKQGKS
2fbj  -----EIVLTQSPAITAASLGQKVTITCSASSSV-----S-SLHWYQQKSGTS
1tet  -----DVLMTQTPLSLPLVSLGDDQASISCKSSQSIHVH-SSGNTYFEWYLQKPGQS
2cgr  -----ELVMTQSPLSLPLVSLGDDQASISCRPSQSLVH-SNGNTYLHWYLQKPGQS

```

```

1hil  PKVLIYWASTRESGVPDRFTGSGSGTDFTLTISVVQEDLAVYYCQNDYSNPLTFGGGTK
2imm  PKLLIYGASTRESGVPDRFTGSGSGTDFTLTISVVQEDLAVYYCQNDHSYPLTFGAGTK
1flr  PKVLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTK
1fvc  PKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGGGTK
1igm  PELRIYDASNLETGVPDRFSGSGSGTDFTFTISSLQPEDFATYYCQQYQNLPLTFGPSTK
1fgv  PKLLIYYTSTLESQVPSRFSGSGSGTDYTLTISLQPEDFATYYCQQGNTLPPTFGAGTK
1vfa  PQLLVYYTSTLADGVPDRFSGSGSGTQYSLKINSLQPEDFGSYVCQHFWSVTPRTFGGGTK
2fbj  PKPWIYEISKLASGVPARFSGSGSGTYSYSLTINTMEAEDAIIYCCQQWYTYPLTFGAGTK
1tet  PKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQGSHPFTFGSGTK
2cgr  PKLLIYRVSNRFSGVPDRFSGSGSGTAFTLKISRVEAEDLGVYFCSQGTHVPYTFGGGTK

```

L1 - K4



1tet

2cgr


KSSQSI VHSSGNTYF

KPSQSLVHSNGNTYL

1tet
2cgr



1tet




2cgr

L3 - κ1


1fgv
1igm
1fvc




1fvc	CQQHYTTPPTF
1igm	CQQYQNLPLTF
1fgv	CQQGNTLPPTF



1fgv




1igm



1fvc

HEAVY CHAIN

HEAVY CHAIN	canonical structure
H1	1, 2, 3
H2	1, 2a, 2b, 2c, 3a, 3b, 3c, 4
H3	-




```

8fab VVQPGRSLRLSCIASGFTFS-N-YGMHWVRQAPG-KGLEWVAVIWY---NGSR-TYYGDS
1ggi ILQPSQTLSTLCSFSGFSLSTYGMGVSWIRQPSG-KGLEWLAHIFW---DG-D-KRYNPS
1h1l LVKPGGSLKLSCAASGFSS-S-YGMSWVRQTPD-KRLEWVAIISN---GGGY-TYYPOS
1fvc LVQPGGSLRLSCAASGFNIK-D-TYIHWVRQAPG-KGLEWVARIYPT---NG-Y-TRYADS
1mfa VARPASVVKMSCKASGYTFT-N-YMHWIKQRPQ-QGLEWIGAIYPG---NS-A-TFYNHK
1igm LVQPGGSLRLSCAASGFTFN-I-FVMSWVRQAPG-KGLEWVSGVFG---SGGN-TDYADA
1fgv LVQPGGSLRLSCATSGYTFT-E-YTMHWMRQAPG-KGLEWVAGINPK---NG-G-TSYADS
1vfa LVAPSQSLITCTVSGFSLT-G-YGVNWVRQPPG-KGLEWLGMIWG---DG-N-TDYNSA
2fb4 VVQPGRSLRLSCSSSGFIFS-S-YAMYWVRQAPG-KGLEWVAIIMD---DGS-D-QHYADS
1gig LVAPSQSLITCTVSGFLLI-S-NGVHWVRQPPG-KGLEWLGVIWA---GG-N-TNYNSA
7fab LVRPSQTLSTLCTVSGTSFD-D-YYTWVRQPPG-RGLEWIGYVFEY---TG-T-TLLDPS
1acy VIKPSQSLSLTCIVSGFSITRTNYCWHWIRQAPG-KGLEWMGRICY---EG-S-IYYSPS
1a1l VIKPSQSLSLTCIVSGFSITRTNYCWHWIRQAPG-KGLEWMGRICY---EG-S-IYYSPS
1tet LKTPGETVRISCKASGYTFT-T-YGMSWVKQTPG-KGFKWGWINTY---SG-V-PTYADD
2fbj LVQPGGSLKLSCAASGFDFS-K-YMWSWVRQAPG-KGLEWIGEIHHP---DS-GTINYTPS
1baf LVKPSQSQSLTCTVTGYSITSD-YAWNWRQFPGNK-LEWGMGYMSY---SG-S-TRYNPS
2cgr LMKPGASVQISCKATGYTFS-E-YWIEWVKERP-G-KGLEWIGEILPG---SG-R-TNYREK
1ind SVKPGGSLKLSCAASGFTLS-G-ETMSWVRQTPG-KRLEWVATLISG---GG-F-TFYSAS
1flr LVQPGRPMKLSVASGFTFS-D-YMNNWVRQSPE-KGLEWVAQIRNKPYNY-E-TYYSDS
1ggc ILQPSQTLSTLCSFSGFSLSTYGMGVSWIRQPSG-KGLEWLAHIFW---DG-D-KRYNPS
    
```

```


8fab VKGRFTISRDNKRTLQYQMNSLRTEDTAVYYCARDP-D-IL-----TAFS-FDY
1ggi LKSRLLKISKDTSNNQVFLKITSVDTADTATYYCVQE-----G-YIY
1h1l VKGRFTISRDNKNTLYLQMSLKSSEDSAMYYCARRERY-----D---EN-G-FAY
1fvc VKGRFTISADTSKNTAYLQMNLSRAEDTAVYYCSRWG-G-D-----G---FY-A-MDY
1mfa FRAKTKLTAVTSTTTAYMELSSLTSEDSAVYYCTRGG-H-----G-YGGDY
1igm VKGRFTITRDNSKNTLYLQMNLSRAEDTAIYYCAKHR-VSYVL-----T-G-FDS
1fgv VKGRFTISVDKSKNTLYLQMNLSRAEDTAVYYCARWR-G-L-----D---VR-Y-FDV
1vfa LKSRLLKISKDNKSKQVFLKMSLHTDDTATYYCARER-D-----Y-R-LDY
2fb4 VKGRFTISRDNKNTLFLQMDSLRPEDTGVFYFCARDGGHFC-SSAS-----CF-G-PDY
1gig LMSRVSISKDNKSKQVFLKMSLQTDATAMYYCARDY-Y-----DYDVFFY-A-MDY
7fab LRGVMTLVNTSKNQFSLRLSSVTAADTAVYYCARNLIA-----G-G-IDV
1acy IKSRSTISRDTSLNKFFIQLISVTNEDTAMYYCSRENHM-----Y---ET-Y-FDV
1a1l IKSRSTISRDTSLNKFFIQLISVTNEDTAMYYCSRENHM-----Y---ET-Y-FDV
1tet FKGRFAFSLSETSASTAYLQINNLKNEDTATYFCARR-S-----W-Y-FDV
2fbj LKDKFIISRDNKNSLYLQMSKVRSEDTALYYCARLH-Y-----YGY-NAY
1baf LRSRISITRDTSKNQFFLQLKSVTTEDTATYFCARG-----W-P-LAY
2cgr FKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCTRQ--Y-----S-S-MDY
1ind VKGRFTISRDNQNNLYLQNLRSSEDTALYFCASH-----R-FVH
1flr VKGRFTISRDD--SSVYLQMNLRVEDMGIYYCTGSY-Y-----G-MDY
1ggc LKSRLLKISKDTSNNQVFLKITSVDTADTATYYCVQE-----G-YIY
    
```

H1 - 1




1ind
1gig
1fgv


AASGFTLSGETMS
TVSGFLLISNGVH
ATSGYTFTEYTMH



1ind



1gig




1fgv


H2 - 2a

1fvc
1fgv
1mfa

RIYPTNGYTR
GINPKNGGTS
AIYPGNSATF




1mfa



1fvc

1fvc
1fgv
1mfa




1fgv

Fab → CDR → hotspot hypothesis
↓ residues determine the binding energy

ANTIBODY-ANTIGEN INTERACTION

Reversible noncovalent interaction forces

- Electrostatic forces
- Hydrogen bonds
- Van der Waals forces
- Hydrophobic forces



Isolated from SARS patient (IgG)

RBD



of the SARS-CoV-2 spike



CR3022

Neutralizing Ab - SARS patient

Crystal structure of SARS-CoV-2 receptor binding domain
in complex with human antibody CR3022 - 3.08 Å





SPIKE

Structure of the SARS-CoV-2 spike glycoprotein


(closed state) 2.80 Å

```


>6VXX_1
MGILPSPGMPALLSLVSLLSVLLMGCVAETGTQCVNLTRTQLPPAYTNSFT
RGVYYPDKVFRSSVLHSTQDLFLPFFSNVTFWFAIHVSGTNGTKRFDNFVLP
FNDGVYFASTEKSNIRGWIFGTTLDSKTQSLILIVNNATNVVLIKVEFQFCN
DPFLGVYYHKNNKSNWMESEFRVYSSANNCTFEYVSQPFMLDLEGKQGNFKNL
REFVFNIDGYFKIYSKHTPINLVRDLFQGFSALEPLVDLPIGINITRFQTL
LALHRSYLTPGDSSSGWTAGAAAYVGYLQPRTFLLKYNENGTITDAVDCAL
DPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNAT
RFASVYAWNRRKISNCVADYSLVYNSASFSTFKCYGVSPTKLNLDLCTNVYA
DSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNLDLSDKVGNY
NYLYRFLFRKSNLKPFERDISEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN
GVGYQYRVVVLSEFLLHAPATVCGPKKSTNLVKNKCVNFNGLTGTGVLT
ESNKKFLFPQQFGRDIADTTDAVRDPQTEILIDITPCSPFGVSVITPGTNTS
NQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGLIGAEHVN
NSYECDIPIGAGICASYQTQTNPSGAGVSQSIIAYTMSLGAENSVAYSN
NSIAIPTNFTISVTTIELPVSMKTSVDCTMYICGDSTECSNLLLQYGSFCT
QLNRLATGIAVEQDKNTQEVFAQVKQIYKTPIKDFGGFNFSQILPDPSPKS
KRSFIEDLFLNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTIVLPLLL
TDEMQYTSALLAGTITSGWTFGAGAALQIPFAMQAYRFNGIGVTQNVLY
ENQKLIANQFNSAIGKIQDSLSSTASALGKLDVNVQNAQALNTLVKQLSSN
FGAISVLDNLDLSDPPEAEVQIDRLITGRLQSLQTYVVTQQLIRAAEIRAS
ANLAATKMSECVLQSKRVDFCGKGYHLMSPQSAPHGVVFLHVTYVPAQEK
NFTTAPAI CHDGAHFPREGVFSNGTHWFVTQRNFYEPQIITDNTFVSGN
CDVVIGVNNVTYDPLQPELDSFKEELDXYFNKHTSPDVDLGDISGINASVV
NIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKSGSRENLYFQGGGSGYI
PEAPRDGQAYVRKDGWVLLSTFLGHHHHHHH
  
```






hydrogen bonds → stabilize




HEAVY CHAIN (V_H)









CONCLUSIONS

WE CONCLUDE THAT...

- Immunoglobulins are essential for antigen recognition and immune response
- The basic immunoglobulin fold is a greek key motif beta sandwich
- Disulfide bridges are important for the maintenance of the Ig structure
- Glycosylations at ASN-297 play an essential role in structure integrity and Fc receptor recognition.
- Mutations at the hinge region (LALA mutants) lead to widening of the Fc opening.
- There are different subtypes of IgG, all of them with similar Fc regions
- The Fc region of IgG1 is conserved among the species analyzed
- Fab interacts with the antigen through hypervariable regions (CDRs), which conform the antigen binding site
- There are conserved CDR structures which are called canonical structures.
- RBD is a highly conserved epitope from Spike that interacts with the Immunoglobulin G

PEM QUESTIONS

1. Which is the main fold of immunoglobulins?

- a. Jelly roll
- b. Greek key sandwich**
- c. TIM barrel
- d. Rossmann fold
- e. beta-barrel

2. In which immunoglobulin domain do IgG1 LALA mutants have the mutations?

- a. CDR1
- b. CDR2
- c. CDR3
- d. Fc region
- e. Hinge region**

3. How many canonical structures have L2 (CDR2 of light chain) domain?

- a. 0**
- b. 1
- c. 2
- d. 3
- e. 4

4. Mark the wrong answer about complementary determining regions (CDRs):

- a) There are CDR in both the light and heavy chains.
- b) Canonical structures refer to a limited number of conformations of the CDRs
- c) They are involved in binding of antigens
- d) They are part of the variable region of immunoglobulins
- e) There are only 2 CDRs for each, the light and heavy chain.

5. Related to the hydrophobicity of immunoglobulins, indicate the true sentences:

- 1) The hydrophobic residues are mostly inside, as they repel water.
- 2) Hydrophilic residues on the surfaces contact with water as it is energetically advantageous
- 3) Hydrophobicity decreases along with distance from the center of the domain
- 4) Light-chain IgG domains are found not to contain regular hydrophobic cores

a. 1,2,3

b. 1,3

c. 2,4

d. 4

e. 1,2,3,4

6. The variable chains in immunoglobulins are essential for the recognition of the antigens. Its acronym CDR comes from the words:

- a. Committee in Defense of the Republic
- b. Complementarity-determining region
- c. Complex-determining region
- d. Canonical-detecting receptor
- e. Common dual region

7. Mark the wrong answer related to the antigen-antibody interaction:

- a) RBD is an epitope from Spike (SARS CoV-2) that interacts with the Immunoglobulin G
- b) Some of the interactions that stabilize the structure are hydrogen bonds
- c) The antigen interacts with both the heavy and the light chain
- d) The binding Ab-Ag is based on reversible covalent interaction forces.
- e) It is based on electrostatic forces, Van der Waals, hydrogen bonds and hydrophobic forces.

8. Mark the correct answer about immunoglobulin structure

- a) The hinge region is the same length in all IgG subtypes (IgG1, IgG2, IgG3 and IgG4) and all the Ig isotypes (IgG, IgM, IgE, IgD and IgA)
- b) Disulfide bonds are not conserved in different IgG subtypes and isotypes
- c) Glycosylation of the Fc region of Immunoglobulins is essential for their correct function
- d) Proline and glycine are mainly found in the beta strands and they are not present in the turns and coils.
- e) The immunoglobulin structure is conformed by multiple alpha helices and none beta-sheets.

9. FcγRI...

- a) Binds to Fc region
- b) Binds to Fab region
- c) Binds to CDRs
- d) Does not bind to any part of immunoglobulines
- e) Binds to antigens

10. Which is the most abundant immunoglobuline in human serum?

- a) Ig A
- b) Ig E
- c) Ig D
- d) Ig G
- e) Ig M

BIBLIOGRAPHY

- Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. *J Mol Biol.* 1997 7;273(4):927-48
- Banach M, Roterman I, Prudhomme N, et al. Hydrophobic core in domains of immunoglobulin-like fold. *J Biomol Struct Dyn.* 2014 32(10):1583-600.
- Das M, Basu C. Glycine rescue of β -sheets from cis-proline. *J Am Chem Soc.* 2012 10;134(40):16536-9
- Davies AM, Sutton BJ. Human IgG4: a structural perspective. *Immunol Rev.* 2015 268(1):139-59
- Feige MJ, Nath S, Catharino SR, et al. Structure of the murine unglycosylated IgG1 Fc fragment. *J Mol Biol.* 2009 21;391(3):599-608
- Harris LJ, Skaletsky E, McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. *J Mol Biol.* 1998 6;275(5):861-72
- Janeway CA Jr, Travers P, Walport M, et al. *Immunobiology: The Immune System in Health and Disease.* 5th edition. New York: Garland Science; 2001. The interaction of the antibody molecule with specific antigen. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK27160/>
- Juraszek J, Rutten L, Blokland S, et al. Stabilizing the closed SARS-CoV-2 spike trimer. *Nat Commun.* 2021 11;12(1):244
- Kiyoshi M, Tsumoto K, Ishii-Watabe A, et al. Glycosylation of IgG-Fc: a molecular perspective. *Int Immunol.* 2017 1;29(7):311-317
- Krapp S, Mimura Y, Jefferis R, et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. *J Mol Biol.* 2003 31;325(5):979-89
- Lu J, Chu J, Zou Z, et al. Structure of Fc γ RI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. *Proc Natl Acad Sci U S A.* 2015 20;112(3):833-8
- Matsumiya S, Yamaguchi Y, Saito J, et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. *J Mol Biol.* 2007 4;368(3):767-79

- North B, Lehmann A, Dunbrack RL Jr. A new clustering of antibody CDR loop conformations. *J Mol Biol.* 2011 18;406(2):228-56
- Rayner LE, Hui GK, Cor J, et al. The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands. *J Biol Chem.* 2015 27;290(13):8420-38
- Sasorith S, Cambon M, Lefranc MP. Immunoglobulin (IG) or antibody glycosylation. 2020. Available from: <https://www.imgt.org/IMGTeducation/IMGTlexique/IG/Glycosylation.html>
- Schlothauer T, Herter S, Koller CF, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. *Protein Eng Des Sel.* 2016 29(10):457-466
- Schroeder HW, Cavacini L. Structure and function of immunoglobulins. *J Allergy Clin Immunol.* 2010 125(2 Suppl 2):S41-52
- Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. *Front Immunol.* 2013 8;4:302
- Tomar DS, Li L, Broulidakis MP, et al. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. *MAbs.* 2017 9(3):476-489
- Valenzuela NM, Schaub S. The Biology of IgG Subclasses and Their Clinical Relevance to Transplantation. *Transplantation.* 2018 102(1S Suppl 1):S7-S13
- Vargas-Madrado E, Lara-Ochoa F, Almagro JC. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. *J Mol Biol.* 1995 1;254(3):497-504
- Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. *Front Immunol.* 2014 20;5:520
- Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.* 2020 16;181(2):281-292
- Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science.* 2020 8;368(6491):630-633